Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Assertio Holdings

Market Cap 152M 132M 123M 115M 215M 14.33B 217M 1.45B 564M 7.05B 570M 558M 24.49B P/E 2026 *
-13.1x
P/E 2027 * 40.5x
Enterprise Value 152M 132M 123M 115M 215M 14.33B 217M 1.45B 564M 7.05B 570M 558M 24.49B EV / Sales 2026 *
1.3x
EV / Sales 2027 * 1.2x
Free-Float
98.57%
Yield 2026 *
-
Yield 2027 * -
1 day+0.09%
1 week+0.09%
Current month+0.26%
1 month+0.38%
3 months+71.28%
6 months+117.59%
Current year+159.10%
1 week 23.48
Extreme 23.48
23.5
1 month 23.36
Extreme 23.36
23.5
Current year 9.11
Extreme 9.11
23.5
1 year 8.61
Extreme 8.61
23.5
3 years 7.71
Extreme 7.7055
96.15
5 years 7.71
Extreme 7.7055
120.15
10 years 7.71
Extreme 7.7055
1,621.19
Director TitleAgeSince
Director/Board Member 26 16/06/2026
Director/Board Member - 16/06/2026
Date Insider Type Main position Quantity % Market Cap.
06-16Tender

Director

-22,250 0.3443%
06-16Tender

Director

-36,438 0.5639%
06-16Tender

General Counsel

-108,771 1.6832%
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+0.09%+137.70%-73.80% 152M
-1.21%-3.04%+39.94%+145.38% 980B
-2.48%-5.18%+51.52%+39.07% 550B
-2.14%-4.94%+16.71%+56.15% 382B
+0.25%-3.09%+23.00%+15.81% 316B
+0.61%-1.69%+25.42%+13.64% 272B
+0.22%-3.10%+24.25%+30.21% 268B
+4.59%+1.98%-40.02%-45.89% 199B
-1.19%-4.95%+16.56%+47.00% 182B
-1.35%-1.46%+14.59%+56.94% 154B
Average -0.26%-2.68%+30.97%+28.45% 330.25B
Weighted average by Cap. -0.78%-3.68%+27.81%+63.69%

Financials

2026 *2027 *
Net sales 117M 102M 94.24M 88.22M 165M 11.01B 166M 1.12B 433M 5.42B 438M 429M 18.82B 127M 110M 102M 95.72M 180M 11.95B 181M 1.21B 470M 5.88B 475M 465M 20.42B
Net income -11.5M -10.03M -9.29M -8.69M -16.3M -1.09B -16.4M -110M -42.7M -534M -43.17M -42.24M -1.85B 400K 349K 323K 302K 567K 37.74M 571K 3.83M 1.49M 18.58M 1.5M 1.47M 64.51M
Net Debt - -
Logo Assertio Holdings
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Employees
53
Date Price Change Volume
15/06/26 23.50 $ +0.09% 274,343
12/06/26 23.48 $ +0.04% 486,525
11/06/26 23.47 $ -0.04% 298,118
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. ASRT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!